TransMedics, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation. Its Organ Care System preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Its Organ Care System incudes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains organs in a near physiologic state and enables surgeons to perfuse and ventilate the organ between the donor and recipient sites; OCS Heart, a portable heart perfusion system that helps to maintain organs in a warm functioning state outside of the body; and OCS Liver, a portable perfusion and monitoring system that maintains organs in a near physiologic state. The company offers its products in the United States and internationally. TransMedics, Inc. is headquartered in Andover, Massachusetts. TransMedics, Inc. is a subsidiary of Transmedics Group, Inc.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone978-552-0900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/2/2020 (Confirmed)
OptionableNot Optionable
TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions
What is TransMedics Group's stock symbol?
TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."
How were TransMedics Group's earnings last quarter?
TransMedics Group Inc (NASDAQ:TMDX) released its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.08. The business earned $7.21 million during the quarter, compared to analyst estimates of $6.67 million. View TransMedics Group's Earnings History.
When is TransMedics Group's next earnings date?
How can I listen to TransMedics Group's earnings call?
TransMedics Group will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for TMDX?
4 Wall Street analysts have issued 12 month price targets for TransMedics Group's stock. Their forecasts range from $28.00 to $37.00. On average, they anticipate TransMedics Group's share price to reach $33.00 in the next year. This suggests a possible upside of 73.0% from the stock's current price. View Analyst Price Targets for TransMedics Group.
What is the consensus analysts' recommendation for TransMedics Group?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TransMedics Group.
Has TransMedics Group been receiving favorable news coverage?
Media coverage about TMDX stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TransMedics Group earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for TransMedics Group.
Are investors shorting TransMedics Group?
TransMedics Group saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,580,000 shares, an increase of 6.0% from the January 15th total of 1,490,000 shares. Based on an average trading volume of 204,600 shares, the short-interest ratio is currently 7.7 days. Approximately 12.8% of the company's stock are short sold. View TransMedics Group's Current Options Chain.
Who are some of TransMedics Group's key competitors?
Some companies that are related to TransMedics Group include InMode (INMD), Natus Medical (NTUS), AxoGen (AXGN), Cutera (CUTR), Zynex (ZYXI), Semler Scientific (SMLR), BioLife Solutions (BLFS), Viewray (VRAY), Stereotaxis (STXS), Rockwell Medical (RMTI), Soleno Therapeutics (SLNO), Fonar (FONR), Edap Tms (EDAP), BioSig Technologies (BSGM) and Second Sight Medical Products (EYES).
What other stocks do shareholders of TransMedics Group own?
Who are TransMedics Group's key executives?
TransMedics Group's management team includes the folowing people:
- Dr. Waleed H. Hassanein, Pres, CEO & Director (Age 51)
- Mr. Stephen Gordon, CFO, Treasurer & Sec. (Age 51)
- Mr. John F. Carey, VP of Operations (Age 55)
- Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 48)
- Mr. Brian Thomson, VP of HR (Age 51)
When did TransMedics Group IPO?
(TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.
Who are TransMedics Group's major shareholders?
TransMedics Group's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Credit Suisse AG (5.35%), Sandhill Capital Partners LLC (3.48%), Emerald Advisers LLC (2.13%), Emerald Mutual Fund Advisers Trust (2.03%) and Roubaix Capital LLC (1.25%). Company insiders that own TransMedics Group stock include David Weill, Edwin M Kania Jr and Tamer I Khayal. View Institutional Ownership Trends for TransMedics Group.
Which institutional investors are buying TransMedics Group stock?
TMDX stock was bought by a variety of institutional investors in the last quarter, including Credit Suisse AG, Emerald Advisers LLC, Sandhill Capital Partners LLC, Emerald Mutual Fund Advisers Trust, State Street Corp, Roubaix Capital LLC, Geode Capital Management LLC and Oregon Public Employees Retirement Fund. Company insiders that have bought TransMedics Group stock in the last two years include David Weill and Edwin M Kania Jr. View Insider Buying and Selling for TransMedics Group.
How do I buy shares of TransMedics Group?
Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is TransMedics Group's stock price today?
One share of TMDX stock can currently be purchased for approximately $19.08.
How big of a company is TransMedics Group?
What is TransMedics Group's official website?
How can I contact TransMedics Group?
TransMedics Group's mailing address is 200 MINUTEMAN ROAD, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]
MarketBeat Community Rating for TransMedics Group (NASDAQ TMDX)
MarketBeat's community ratings are surveys of what our community members think about TransMedics Group and other stocks. Vote "Outperform" if you believe TMDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TMDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
